A Reversal for Axogen Incorporated (NASDAQ:AXGN) Is Near. The Stock Has Decrease in Shorts

December 7, 2017 - By Vivian Park

 A Reversal for Axogen Incorporated (NASDAQ:AXGN) Is Near. The Stock Has Decrease in Shorts

The stock of Axogen Incorporated (NASDAQ:AXGN) registered a decrease of 9.61% in short interest. AXGN’s total short interest was 960,000 shares in December as published by FINRA. Its down 9.61% from 1.06M shares, reported previously. With 199,700 shares average volume, it will take short sellers 5 days to cover their AXGN’s short positions. The short interest to Axogen Incorporated’s float is 4.16%.

The stock increased 1.34% or $0.35 during the last trading session, reaching $26.45. About 338,153 shares traded or 19.22% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since December 7, 2016 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $901.78 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 7 analysts covering AxoGen (NASDAQ:AXGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 16 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Thursday, November 2. The firm earned “Outperform” rating on Tuesday, November 21 by Leerink Swann. The company was downgraded on Thursday, November 3 by Lake Street. The stock has “Buy” rating by Roth Capital on Monday, September 11. Zacks upgraded AxoGen, Inc. (NASDAQ:AXGN) rating on Tuesday, August 11. Zacks has “Hold” rating and $4 target. The firm has “Outperform” rating by Wedbush given on Friday, August 28. The firm has “Buy” rating given on Monday, August 21 by Cantor Fitzgerald. The company was maintained on Tuesday, November 21 by Wedbush. The stock has “Outperform” rating by Wedbush on Monday, November 7. The stock has “Buy” rating by Lake Street on Tuesday, November 22.

More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Streetinsider.com which released: “Jefferies Starts AxoGen, Inc. (AXGN) at Buy, Best Growth Story in Medtech” on November 30, 2017. Also Streetinsider.com published the news titled: “AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day” on November 21, 2017. Nasdaq.com‘s news article titled: “AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference” with publication date: November 14, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.